Bionano Genomics Announces Record Number of Presentations on Optical Genome Mapping and Structural Variation at the 2021 Annual Clinical Genetics Meeting of the ACMG
“ACMG this year has the greatest number of presentations featuring Bionano data to date,” commented
Blood Cancers Oral and Poster Presentations:
- Platform Presentation,
Thursday, April 15, 2021 ,5:30 pm . OP340 – Optical Genome Mapping for Assessment of Genomic Aberrations in Acute Myeloid Leukemia: A Multicenter Evaluation - eP085 – Efficient workflow for detection of clinically relevant abnormalities in leukemias according to NCCN guidelines
- eP068 – Optical Genome Mapping Detects Rare Genetic Drivers in Pediatric B-Lymphoblastic Leukemia
Prenatal Oral and Poster Presentations:
Product Theater (available on demand): Next-Generation Cytogenomic Characterization of Prenatal Cases by Optical Genome Mapping- eP501 – Generation of a Prenatal Workflow for Identification of Structural Variation by Optical Genome Mapping (OGM)
- eP502 – Next-Generation Cytogenomic Characterization of Prenatal Cases by Optical Genome Mapping
Post-Natal Oral and Poster Presentations:
- Platform Presentation, Wednesday, 4/14,
4:15 pm , part of Scientific Concurrent Session “Hot Topics: Pushing the Boundaries of Genome Sequencing” – Clinically Relevant Genes Hiding In Plain Sight And How Long Range Technologies Resolve Them - eP436 – Identification of Structural Variation in Constitutional Disorders by Optical Genome Mapping
- eP406 – Optical Genome Mapping Enables Constitutional Chromosomal Aberration Detection: Proof-of-Principle Study with 85 Samples
- eP294 – High Throughput Analysis of Disease Repeat Expansions and Contractions by Optical Mapping
- eP447 – Improving and Accelerating Clinical Molecular Diagnosis of Severe Hemophilia A with Optical Genome Mapping Technology
- eP370 – Fascioscapulohumeral Muscular Dystrophy Genetic Testing by Optic Mapping
Solid Tumors Poster Presentations:
- eP083 – Clinical Utility of Optical Genome Mapping (OGM) in Cytogenetic Analysis of Brain Tumors
- eP388 – Optical Genomic Mapping Reveals Balanced and Unbalanced Cytogenetic Findings Associated with Tumor-forming Potential in a Prostate Cancer Cell line (M2205)
Other Bionano Poster Presentations:
- eP407 – NeuroSCORE: A Genome-wide OMICs Based Model to Identify Disease Associated Genes of the Central Nervous System
- eP365 – PRKX/PRKY-Mediated Xp;Yp Translocations: A Significant Contributor to SRY-Positive 46,XX TDSD and Potential Risk of Recurrence in Common Yp Inversion Carriers
More details can be found at https://www.acmgmeeting.net/acmg2021/Public/mainhall.aspx
About the ACMG Meeting
The ACMG Meeting is the genetics meeting most focused specifically on the practical applications of genetic discoveries to clinical medicine. Topics range from common conditions to rare diseases. The ACMG Annual Meeting attracts medical and scientific leaders from around the world who are working to apply research in genetics and the human genome to the diagnosis, management, treatment and prevention of genetic conditions and rare and common diseases in patients in the clinical setting.
About
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release; our presence in the medical genetics community; our ability to address barriers to adoption in
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations and
Media Contact:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics